Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel A Funt

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Nature Communications|April 12, 2022
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinomaJeppe Sejerø Holm, Samuel A Funt, Annie Borch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Science Translational Medicine|August 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockadeRonglai Shen, Michael A Postow, Matthew Adamow, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapySiri Amanda Tvingsholm, Marcus Svensson Frej, Vibeke Mindahl Rafa, et al.
Frontiers in Immunology|April 18, 2024
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognitionAnnie Borch, Ibel Carri, Birkir Reynisson, et al.
The Journal of Clinical Investigation|September 8, 2020
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursorJustin Taylor, Mark Ta Donoghue, Caleb Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancerBrendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
Clinical Genitourinary Cancer|June 8, 2022
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant ChemotherapyMin Yuen Teo, Brendan J Guercio, Arshi Arora, et al.
JCO Precision Oncology|June 22, 2022
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular PhenotypeNima Almassi, Karissa Whiting, Antoun Toubaji, et al.
Nature Immunology|July 28, 2022
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccineRamin Sedaghat Herati, David A Knorr, Laura A Vella, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Nature Communications|April 12, 2022
Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinomaJeppe Sejerø Holm, Samuel A Funt, Annie Borch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Science Translational Medicine|August 26, 2021
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockadeRonglai Shen, Michael A Postow, Matthew Adamow, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapySiri Amanda Tvingsholm, Marcus Svensson Frej, Vibeke Mindahl Rafa, et al.
Frontiers in Immunology|April 18, 2024
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognitionAnnie Borch, Ibel Carri, Birkir Reynisson, et al.
The Journal of Clinical Investigation|September 8, 2020
Germ cell tumors and associated hematologic malignancies evolve from a common shared precursorJustin Taylor, Mark Ta Donoghue, Caleb Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancerBrendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
Clinical Genitourinary Cancer|June 8, 2022
Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant ChemotherapyMin Yuen Teo, Brendan J Guercio, Arshi Arora, et al.
JCO Precision Oncology|June 22, 2022
Clinical and Genomic Characterization of Bladder Carcinomas With Glandular PhenotypeNima Almassi, Karissa Whiting, Antoun Toubaji, et al.
Nature Immunology|July 28, 2022
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccineRamin Sedaghat Herati, David A Knorr, Laura A Vella, et al.
Pageof 8